PMDA Notice: Nitrosamine Compounds Detected (Sertraline, Maprotiline Hydrochloride)
「ニトロソアミン化合物検出のお知らせ（セルトラリン、マプロチリン塩酸塩）」を掲載しました
Published: 2026-10-05 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-10-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
The Pharmaceuticals and Medical Devices Agency (PMDA) posted a safety-information notice on its drug safety updates page, titled in Japanese as a notice of nitrosamine compound detection concerning sertraline and maprotiline hydrochloride. This is a government announcement dated 2026-10-05; the provided metadata gives no further detail on the findings, affected products, or any requested measures.
Business Impact
Companies that manufacture, import, distribute, or prescribe medicines containing these active ingredients may wish to check whether the notice relates to their products. The practical effect cannot be determined from the metadata provided.
Recommended Action
Review the official PMDA notice at the source URL to confirm which products, if any, are affected and what the agency has stated.